ReviewCVIR endovascular2021
Endovascular approaches in pediatric interventional oncology.
Review in CVIR endovascular, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06562673 (Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Direct-stick embolization to treat hematochezia secondary to rectally metastatic sacral neuroblastoma.JPGN reports · 2026Article
- Preoperative Angioembolization of Pediatric Solid Tumors: Does It Facilitate the Surgeon's Task?Maedica · 2025Article
- Pain Management in Pediatrics: What the IR has to Offer.Cardiovascular and interventional radiology · 2025Review
- The Role of IR in Pediatric Liver Cancer.Seminars in interventional radiology · 2025Review
- Fundamentals of Pediatric Cancer: How Pediatric Pathology and Infrastructure of Clinical Trials Impact Contemporary Interventional Oncology in Children.Seminars in interventional radiology · 2025Review
- Review
- Article
- Embolization in Pediatric Patients: A Comprehensive Review of Indications, Procedures, and Clinical Outcomes.Journal of clinical medicine · 2022Review
- Paediatric IR: the evidence for best practice is growing.CVIR endovascular · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The demand for interventional oncological (IO) treatment of pediatric cancers is becoming increasingly common, at least at several tertiary care institutions. The data and techniques used in pediatric IO are largely extrapolated from experience in adult patients. The management of pediatric tumors differs from that in adults in several categories, such as, the curative intent of treatment, wide use of general anesthesia, aggressive pain management, potentially longer hospital stay, variation in chemotherapy dosing etc. Additionally, pediatric cancers are managed by protocols directed by national and international oncology groups such as the Children's Oncology Group (COG). Consequently, the translation and adoption of these techniques is gradual, but there is a noticeable uptrend due to the growing need. This review will update the current endovascular IO treatments for common pediatric liver, renal, bone and soft tissue tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.